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Tuberculosis (TB) is a disease of antiquity. Yet TB today still causes more adult deaths than any
other single infectious disease. Recent studies show that contrary to the common view postulating
an animal origin for TB, Mycobacterium tuberculosis complex (MTBC), the causative agent of TB,
emerged as a human pathogen in Africa and colonized the world accompanying the Out-of-
Africa migrations of modern humans. More recently, evolutionarily ‘modern’ lineages of MTBC
expanded as a consequence of the global human population increase, and spread throughout
the world following waves of exploration, trade and conquest. While epidemiological data
suggest that the different phylogenetic lineages of MTBC might have adapted to different
human populations, overall, the phylogenetically ‘modern’ MTBC lineages are more successful
in terms of their geographical spread compared with the ‘ancient’ lineages. Interestingly, the
global success of ‘modern’ MTBC correlates with a hypo-inﬂammatory phenotype in macrophages,
possibly reﬂecting higher virulence, and a shorter latency in humans. Finally, various human gen-
etic variants have been associated with different MTBC lineages, suggesting an interaction
between human genetic diversity and MTBC variation. In summary, the biology and the epidemiol-
ogy of human TB have been shaped by the long-standing association between MTBC and its
human host.
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1. INTRODUCTION
Tuberculosis (TB) remains a major global health pro-
blem. Ten million new TB cases and 2 million deaths
are estimated to occur each year, more than any time
in history [1]. Furthermore, an estimated 2 billion
people are thought to be latently infected, providing
a large reservoir for active TB that will last for decades
[2]. Even though during the last centuries TB used to
cause up to half of all human deaths in Europe and
North-America [3], today the disease affects primarily
the developing world. Notably, some of the largest
emerging economies including China and India
remain among the 22 high-burden countries for TB
identiﬁed by the World Health Organization (WHO).
These two countries collectively accounted for more
than one-third of all new TB cases in 2009 [1].
TB is the prototype of a disease of poverty [4]. In
addition to the well-established environmental and
socio-economical risk factors for TB [5], recent times
have witnessed the appearance of new forces driving
the global TB pandemic: HIV/AIDS and the emer-
gence of antimicrobial resistance. Since its initial
appearance in the 1980s, the HIV/AIDS pandemic
had a dramatic effect on TB incidence, particularly in
sub-Saharan Africa [6]. Moreover, the introduction of
chemotherapy against TB, which started in the 1940s,
has led to increasing levels of drug resistance [7]. The
global emergence of multi-drug resistance has initiated
the post-antibiotic era, making TB essentially incurable
in many parts of the world [8]. Left untreated TB kills
50 per cent of patients on average [9], with HIV co-
infected patients facing an even higher risk of death
[10]. The only available vaccine against TB is ‘bacille
Calmette Gue ´rin’ (BCG), an attenuated form of
Mycobacterium bovis, which is a pathogen of cattle
(further discussed below) [11]. However, BCG only
protects young children against TB meningitis, the
most severe form of the disease. Why BCG does not
protect adults reliably against the classical pulmonary
form of TB is unknown [12].
TB is an ancient disease [13]. Recent data show
that, contrary to the traditional belief linking the
origin of TB to the development of agriculture and
animal domestication during the Neolithic transition
approximately 10 000 years ago, TB has been affecting
humans for much longer. Hence, the long-term inter-
action between the TB microbe and its human host
raises the question as to whether coevolution has
occurred and if it can be detected. Here, I start by
summarizing some of the most important features of
TB and the agents causing it. I then discuss several
recent ﬁndings which support the notion of coevolu-
tion in human TB. Some of the points discussed are
purely speculative. Yet, I am addressing them in the
hope of fuelling future research.
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TUBERCULOSIS COMPLEX
TB is caused by a group of phylogenetically closely
relatedbacteria,collectivelyknownastheMycobacterium
tuberculosis complex (MTBC) [14]. TB in humans is
primarily caused by M. tuberculosis and Mycobacterium
africanum, a phylogenetic variant of MTBC limited to
West Africa [15]. In addition, several animal-adapted
members of MTBC exist, which affect a range of
wild and domestic animal species [16]. These include
M. bovis (a pathogen of cattle), Mycobacterium caprae
(sheep and goats), Mycobacterium microti (voles) and
Mycobacterium pinnipedii (seals and sea lions). Mycobac-
terium bovis used to be a signiﬁcant cause of human
TB, primarily in children who consumed raw milk
[17]. However, M. bovis infections in humans decreased
markedly following the introduction of pasteurization
and meat-control practices. Moreover, M. bovis does
not easily transmit between humans and, similarly,
while M. tuberculosis has been isolated from various
animal species, including cattle, there is currently no
evidence of animal-to-animal transmission of M. tuber-
culosis or M. africanum. Hence, the different members
of MTBC appear to be best adapted to their particular
host species [18].
One particular member of MTBC deserves special
mention: Mycobacterium canettii, which is part of the
so-called ‘smooth TB bacilli’ [19]. This somewhat
enigmatic microbe was ﬁrst described in the 1960s,
and so far only about 60 isolates have been reported
[20]. Intriguingly, the large majority of these were
recovered from TB patients in Djibouti or from indi-
viduals who spent some time at the Horn of Africa
prior to developing TB. Mycobacterium canettii differs
in many ways from classical MTBC. This organism
produces smooth and shiny colonies on solid growth
media, which are distinct from the rough colony mor-
phology characteristic of classical MTBC. Moreover,
M. canettii and the other ‘smooth TB bacilli’ harbour
much more genetic diversity compared with classical
MTBC (ﬁgure 1). Most importantly, M. canettii
shows clear evidence of ongoing horizontal gene
exchange (ﬁgure 1), which does not occur in classical
MTBC [21,22]. This latter observation, combined
with the lack of evidence for human-to-human trans-
mission of M. canettii, and the fact that M. cannettii
clinical isolates are rare, suggests that this organism
is an opportunist, and that an environmental reservoir
exists somewhere in the Horn of Africa [23].
By contrast, M. tuberculosis and M. africanum are
obligate human pathogens with limited survival out-
side of the human body and no known animal
reservoir [15]. Moreover, these microbes have to
cause active disease in order to transmit to secondary
hosts [24]. In other words, in MTBC there is a
direct link between virulence and transmission,
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Figure 1. Phylogenetic relationship between ‘smooth’ tubercle bacilli and classical MTBC. Multi-locus sequence data of six
housekeeping genes show that the smooth tubercle bacilli are more genetically diverse than MTBC. The network structure
of the phylogenetic relationships between members of the smooth tubercle bacilli indicates ongoing horizontal gene exchange,
which is absent in MTBC. Adapted from Gutierrez et al.[ 19].
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Because latently infected individuals are considered
non-infectious [2], global efforts in controlling TB
almost exclusively focus on detecting and treating
patients with active TB [1]. However, because culture
facilities are often not available, most places still diag-
nose TB by sputum-smear microscopy. Unfortunately,
this technique suffers from limited sensitivity and up to
50 per cent of active TB cases are routinely missed.
Individuals harbouring the largest numbers of acid-
fast bacilli in their sputum are considered the most
infectious [27].
MTBC can infect virtually any organ. However,
from a public health point of view, classical pulmonary
TB is the most important form of the disease because
of its infectious nature. One of the main immuno-
pathological features of active pulmonary TB is the
formation of lung cavities. These structures tend to
harbour large numbers of bacteria, which is why cavi-
tary TB tends to be the most infectious form of the
disease. By contrast, extrapulmonary TB is generally
non-infectious and therefore has a lower public
health priority [1].
3. THE ORIGIN OF HUMAN TUBERCULOSIS
Until a few years ago, the prevalent view was that TB
originated in animals and was transferred to humans
during the Neolithic transition [28]. However, com-
parative genomics and population genetic studies
have challenged this notion [29,30]. In particular,
M. bovis and the other animal-adapted members of
MTBC have a genome which is about 60 000 base
pairs smaller than the genome of the human-adapted
M. tuberculosis [14,31]. Because MTBC exhibits essen-
tially no ongoing horizontal gene exchange [21],
the genomic regions present in M. tuberculosis but
absent from M. bovis represent deletions in the latter
rather than insertions in the former. More recently,
phylogenetic analyses of 89 gene concatenates in 108
strains representative of the global MTBC diversity
revealed that the animal-adapted members of the
MTBC clustered together, representing an ingroup
with respect to the global phylogeny of MTBC,
while all other taxa represented human-adapted
forms [32]. In summary, although M. tuberculosis and
M. bovis do share a common ancestor, the most parsi-
monious scenario suggests that humans gave TB to
animals rather than the other way around [28]. This
latter observation also suggests that TB in humans
pre-dates the Neolithic transition.
That human TB appears to be signiﬁcantly older
than approximately 10 000 years is supported by sev-
eral additional lines of evidence. A recent study from
Turkey reported a 500 000 year old fossil of Homo erec-
tus, which shows lesions characteristic of TB [33].
Maybe not surprisingly, this ﬁnding is controversial,
as it suggests that TB predated the origin of modern
humans. Similarly, a study by Gutierrez et al.[ 19]p r o -
posed that M. canettii and the other smooth TB bacilli
represent a group of organisms likely to contain the
ancestor of MTBC. The authors used DNA sequence
data of six housekeeping genes and calculated an
approximate age of 3 million years for the origin of
what they have been referring to as ‘Mycobacterium pro-
totuberculosis’ (ﬁgure 1). However, these dating results,
too, have been contested [34].
More recently, Comas et al.[ 35] generated the ﬁrst
whole-genome-based global phylogeny of human-
adapted MTBC (ﬁgure 2a). This analysis revealed
that the two MTBC lineages generally referred to as
M. africanum (lineage 5 and 6 in ﬁgure 2a) are the
most basal. These two lineages occur almost exclu-
sively in West Africa for reasons unknown (ﬁgure 2b)
[15]. Furthermore, Africa is the only region of the
world that harbours all six main human-adapted
MTBC lineages (ﬁgure 2b)[ 37]. In other words,
Africa harbours the largest diversity of human-adapted
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Figure 2. Global phylogeography of MTBC. (a) Global phylogeny of human-adapted MTBC is based on 22 whole-genome
sequences. Adapted from Comas et al.[ 35]. (b) Global distribution of the six main human-adapted MTBC lineages. Coloured
dots represent the dominant MTBC lineage(s) in each country. Adapted from Gagneux et al.[ 36].
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reminiscent of the situation in modern humans; i.e.
Homo sapiens from Africa are known to be phylogeneti-
cally ‘ancestral’ and harbour most of the known
human genetic diversity [38]. Finally, human-adapted
MTBC exhibits a phylogeographic population struc-
ture with different lineages associated with different
human populations (ﬁgure 2)[ 36].
Based on these observations, Hershberg et al.[ 32]
proposed an evolutionary scenario for the origin and
global spread of human TB. This scenario was sup-
ported by multi-locus sequence data from 108 global
MTBC strains and postulates that human MTBC ori-
ginated in Africa and accompanied the Out-of-Africa
migrations of modern humans approximately 70 000
years ago (ﬁgure 3). While two phylogenetically
‘ancient’ MTBC lineages remained in Africa, other
lineages left Africa and spread into Eurasia where
the three phylogenetically ‘modern’ lineages seeded
Europe, India and China, respectively. These areas
experienced strong human population growth during
the last few centuries. As a consequence, the MTBC
populations in these areas expanded, and concomi-
tantly spread globally through waves of human
exploration, trade and conquest. In support of this
scenario, a study by Wirth et al.[ 39] based on mini-
satellite data in another gobal collection of MTBC
isolates detected molecular signatures of recent (i.e.
less than 200 years) population expansion in the differ-
ent MTBC populations. These signatures were more
pronounced in MTBC populations from Europe and
Asia compared with those from Africa.
Assuming the ‘Out-of-and-back-to-Africa’ scenario
of TB evolution by Hershberg et al is correct, then
several important questions remain. For a long time,
the general view was that TB did not exist in the
Americas before European contact [40]. This notion
was to a large extent based on the high susceptibility
to TB observed in Native Americans. This gave rise
to the so-called ‘Virgin soil’ hypothesis, according to
which Native Americans were immunologically naive
because they (presumably) had not been exposed to
TB before European contact [41]. This view has
now changed quite radically, with an emerging consen-
sus among historians and paleopathologists suggesting
that TB was in fact present in pre-Columbian America
[42]. Note that Native Americans remain highly sus-
ceptible to TB, but other, more general risk factors
(a)
(b)
Figure 3. ‘Out-of-and-back-to-Africa’ scenario for the evolutionary history of human TB. Adapted from Hershberg et al.[ 32].
(a) MTBC originated in Africa and some lineages accompanied the Out-of-Africa migrations of modern humans. (b) The
three evolutionary ‘modern’ MTBC lineages seeded Europe, India and China, respectively, and expanded as a consequence
of the sharp increases in human populations in these regions starting a few centuries ago (each dark grey dot corresponds
to 1 million people). These lineages then spread throughout the world via exploration, trade and conquest. Lineage colours
correspond to ﬁgure 2.
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phenomenon, including poor living and nutritional
conditions and alcohol abuse [41]. Even though
ancient DNA studies were able to detect mycobacterial
DNA in pre-Columbian human remains [43], the
more detailed characteristics of this DNA remains
unknown. In other words, we do not know what the
exact a etiologic agent of TB was at the time [42].
Today, by far, most TB in the Americas is caused by
lineage 4, also known as the Euro-American lineage
(ﬁgure 2b)[ 37]. Future studies will tell whether pre-
Columbian TB was caused by MTBC related to
Asian forms, as would be expected given the original
human colonization of the Americas via the Bering
Strait. Alternatively, pre-Columbian TB might have
been caused by mycobacterial lineages which are
now extinct, perhaps because they were outcompeted
by lineage 4/Euro-American lineage following the mas-
sive inﬂux of Europeans with active or latent TB into
the Americas between the early eighteenth and early
twentieth century [44].
Another open question is why despite centuries of
cross-Atlantic slave trade, M. africanum lineages are
almost never isolated in the Americas [15]. It is reason-
able to assume that a proportion of the 10–15 million
African slaves taken to the Americas would have been
latently infected with TB. Similar to the argument
above, perhaps, M. africanum in the Americas was out-
competed by lineage 4 following the European exodus
into America. Interestingly, there is evidence that at
least in some areas of West Africa, M. africanum has
been decreasing and M. tuberculosis increasing over the
last few decades [45]. We will return to the phenotypic
differences between M. africanum and ‘modern’ MTBC
which could account for this phenomenon further below.
In summary, the available evidence suggests that
human MTBC originated in Africa and has been
infecting humans for millennia. Considering this long-
standing host–pathogen association, one wonders
whethersomedegreeofcoevolutionmighthaveoccurred
between MTBC and its human host.
4. SIGNS OF HOST–PATHOGEN COEVOLUTION
IN HUMAN TUBERCULOSIS
Host–pathogen coevolution can broadly be deﬁned as
‘reciprocal, adaptive genetic changes in interacting
host and pathogen species’ [46]. While such changes
will be difﬁcult to detect in humans, approaching the
subject from the pathogen side appears more prom-
ising. Over recent years, data have accumulated
suggesting that the different MTBC lineages might
be adapted to different human populations. Not only
does MTBC exhibit a global biogeographic population
structure (ﬁgure 2b), but the associations between the
particular MTBC lineages and human populations are
maintained in cosmopolitan settings where human
populations and their associated MTBC strains experi-
ence at least some degree of intermingling [21,47,48].
Moreover, a study in San Francisco found that MTBC
lineages primarily transmitted among their sympatric
host populations (ﬁgure 3)[ 36]. Intriguingly, trans-
mission of allopatric strains was strongly associated
withknownriskfactorsforTBsuchasHIVco-infection.
Whether these ﬁndings reﬂect true biological phenom-
ena rather than mere sociological factors need to
be explored further. Nevertheless, they are consistent
with host-speciﬁc adaptation of MTBC lineages, which
if conﬁrmed, would also be consistent with past
host–pathogen coevolution.
5. IMMUNE SUBVERSION INSTEAD
OF EVOLUTIONARY ARMS-RACE
If host-speciﬁc pathogen adaptation has occurred in
human MTBC, we would be most likely to detect the
associated molecular changes in parts of the MTBC
genome that interact with the human immune system,
i.e. in genes encoding antigens. More generally, if
host–pathogen coevolution is occurring in MTBC, we
should be able to detect its signature in antigenic
genes. One of the key features of host–pathogen coevo-
lution in other disease systems is the ongoing
evolutionary arms-race between the pathogen and the
host immune system [49]. Many pathogenic viruses,
bacteria and protozoa evade host immunity by varying
their antigenic genes. Is MTBC using a similar strategy
to evade human immune responses? Comas et al.[ 35]
aimed at answering this question by comparing the gen-
etic diversity in different gene classes of MTBC. The
authors sequenced the genomes of 21 human MTBC
strains representative of the global diversity of MTBC.
As a proof of concept, Comas et al. ﬁrst showed that,
as expected, essential genes were more evolutionarily
conserved than non-essential genes (ﬁgure 4). Sur-
prisingly however, the authors found that the known
human T-cell epitopes of MTBC were the most con-
served regions of the MTBC genome (ﬁgure 4). In
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Figure 4. Preferential sympatric transmission of MTBC
lineages in San Francisco. The number of secondary TB
cases generated between 2001 and 2009 is plotted as a func-
tion of the number of index cases (secondary case rate ratio)
and the human population in which these secondary cases
occurred. In each human population, the number of second-
ary cases caused by sympatric MTBC lineages was
signiﬁcantly higher compared with the secondary cases
caused by allopatric lineages. Sympatric and allopatric
lineages were deﬁned based on their usual phylogeographic
association shown in ﬁgure 2. (Red, lineage 4 or Euro-
American lineage; Blue, lineage 2 or East-Asian lineage;
Pink, lineage 1 or Indo-Oceanc lineage.) Adapted from
Gagneux et al.[ 36].
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topes analysed had no amino acid change at all. Based
on their ﬁndings, the authors speculated that the
immune responses elicited by these T-cell epitopes
might in fact be beneﬁcial to the bacteria rather than
to the host. In other words, rather than escaping host
immunity, MTBC wants to be recognized because the
ensuing host immune responses contribute to tissue
destruction and the formation of cavities in the host
lung, which ultimately enhances transmission [50].
The notion that T-cell immunity contributes to the for-
mation of lung cavities in TB patients is supported by
the observation that HIV-positive TB patients with
low CD4 T-cell counts are less likely to present with
cavitary TB than HIV-positive patients with higher
CD4 cell counts [6]. In summary, the reason these T-
cell epitopes are evolutionarily hyper-conserved might
be that they perform an essential function in the sense
of contributing to the successful spread of MTBC.
This of course does not exclude the possibility that
MTBC might harbour antigenic variation in other
regions of its genome [51].
6. HUMAN DEMOGRAPHY AND THE EVOLUTION
OF VIRULENCE
Despite the lack of genetic diversity in the known T-cell
epitopes, much genetic diversity exists within and
between MTBC lineages, which so far has not been
explored experimentally [32]. This diversity could
be at the basis of the phenotypic variation, which
is increasingly being reported in human-adapted
MTBC [52,53]. Our unpublished data from whole
genome comparisons in MTBC show that two
human-adapted MTBC strains can differ by more
than 1700 single-nucleotide polymorphisms (SNPs),
which is close to the genetic distance between
M. tuberculosis and the cattle-adapted M. bovis.
Furthermore, about two-thirds of these SNPs are non-
synonymous (ﬁgure 4), and the majority of these
non-synonymous SNPs are predicted to have a
functional consequence [32]. Thus, any of these differ-
ences on their own, or in combination, could inﬂuence
the various MTBC phenotypes [52].
As mentioned above, the six main human-adapted
lineages of MTBC can be divided into evolutionarily
‘ancient’ and ‘modern’. As can be seen from ﬁgure 2,
the three ‘modern’ lineages are overall more successful
than the other lineages in terms of their geographical
spread [37]. What could account for this differential
success? According to the evolutionary scenario by
Hershberg et al.[ 32]( ﬁgure 3), the ‘modern’ lineages
expanded as a consequence of the sharp increases
in human populations during the last few centuries in
Europe, India and China. Ecological theory pre-
dicts that when virulence is positively correlated with
transmission, as is the case in TB, access to a larger
number of susceptible hosts favours higher virulence
and a shorter latency period [26]. If we believe the pro-
posed coevolutionary history of MTBC with humans,
most of this evolutionary history would have occurred
during hunter–gatherer times, when human population
densities were low. In fact, it has been argued that the
characteristic latency period of human TB, followed
by reactivation and active disease several decades later,
might have evolved to allow MTBC to access new
birth cohorts of susceptible hosts and, at the same
time, avoid a burn-out situation whereby all suscepti-
ble hosts would be decimated by an overly virulent
pathogen [54]. By contrast, high host densities, similar
to the ones encountered in the crowded cities of eight-
eenth and nineteenth century Europe [3], might have
selected for less ‘prudent’ forms of MTBC [55], as
access to susceptible hosts was no more a limiting
factor. Based on this scenario, and because the
‘modern’ MTBC lineages were exposed to this rapid
human expansion, we would predict that ‘modern’
MTBC will be more virulent and associated with a
shorter latency period compared with ‘ancient’ MTBC.
Intriguingly, several recent data from the laboratory
and the ﬁeld support this prediction.
7. FROM MYCOBACTERIUM TUBERCULOSIS
COMPLEX GENOTYPE TO PHENOTYPE
The ﬁrst human cells encountered by MTBC during
the course of an initial infection are believed to be
alveolar macrophages [24]. These cells engulf
MTBC but cannot destroy them. In fact, MTBC
evolved mechanisms to inhibit endosome maturation
and phagosome–lysosome fusion, which allows the
bacteria to survive and even multiply within these
macrophages [56]. Human monocyte-derived macro-
phages (MDMs) have thus been used as a model to
study the cell biology and early mechanisms of infec-
tion in TB. Portevin et al.[ 57] recently used such a
model to study the innate immune responses to 28
MTBC strains spanning the whole global diversity of
human MTBC. The authors used MDMs from eight
different healthy donors, infected them with one of
each of these 28 strains, and measured a series of cyto-
kines and chemokines after 24 h of infection. The
results showed that the MDMs infected with different
MTBC strains differed markedly in the levels of cyto-
kines and chemokines produced. Interestingly, MDMs
infected with ‘modern’ strains produced signiﬁcantly
less pro-inﬂammatory cytokines compared with
‘ancient strains’ (ﬁgure 5). The same results were
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Figure 5. Human T-cell epitopes of MTBC are evolutiona-
rily hyper-conserved. Ratio of non-synonymous mutations
to synonymous mutations in different gene classes based
on whole genome sequencing of 22 MTBC strains represen-
tative of the global MTBC diversity. Adapted from Comas
et al.[ 35].
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dendritic cells or bone marrow-derived murine macro-
phages. Furthermore, the results were reproducible
across the eight human donors. Previous work has
shown that low pro-inﬂammatory innate immune
responses to MTBC infection were associated with a
higher virulence in animal models [58,59]. Moreover,
work from the 1960s showed that MTBC strains from
South India were less virulent in guinea pigs than
strains from the UK [60]. We now know that these
South-Indian strains belonged to the ‘ancient’ lineage 1
while most strains in the UK belong to the ‘modern’
lineage 4 (ﬁgure 2).
In a molecular epidemiological study of TB trans-
mission in the Gambia, de Jong et al.[ 61] recruited
317 TB patients and followed their 1808 HIV-negative
household contacts during 2 years. The authors then
categorized these contacts depending on the MTBC
lineage the index case was infected with, and deter-
mined how many contacts would become newly
infected (i.e. indicating transmission from the index
case) and how many would develop active TB. The
results showed that, while there was no difference in
transmission, contacts exposed to ‘modern’ MTBC
were more likely to develop active TB compared with
individuals exposed to ‘ancient’ MTBC (ﬁgure 6).
Takentogether,theseobservationsareconsistentwith
the notion that ‘modern’ strains have evolved a strategy
of higher virulence and shorter latency, perhaps to
better adapt to the increasing availability of susceptible
hosts brought by the large human population increases
of the last few centuries.
8. THE ROLE OF HUMAN GENETIC DIVERSITY
So far our discussion has primarily focused on the
pathogen, maybe because the case for unilateral ‘host-
speciﬁc pathogen adaptation’ might be more plausible
and easier to demonstrate than true reciprocal ‘coevolu-
tion’ between MTBC and humans, given the shorter
generation-time of the former. Nevertheless, variation
in TB susceptibility across humans is well established
and best illustrated by early twin studies [62]. Since
then, many TB susceptibility and resistance loci have
been reported in humans [63]. Except fora fewextreme
and very rare cases of Mendelian disorders, TB is a
classical example of a complex disease in which each
individual TB-associated genetic locus contributes a
small proportion of the observed variation in disease
susceptibility. Ten years ago, a theoretical study
explored whether the natural selection for resistance to
TB could have been sufﬁciently intense to account for
the sharp decrease in TB-associated mortality during
the later half of the nineteenth century in Europe [3].
The authors concluded that even when applying a
time window of 300 years, time would not have been
enough to increase the frequency of TB resistance loci
to any signiﬁcant level in these European populations
[64].However,wenow know thatTBhasbeenaffecting
humans for millennia, albeit perhaps imposing lower
mortality on low-density hunter–gatherer populations
(ﬁgure 7).
One of the most important questions in TB research
is why only approximately 10 per cent of latently
infected individuals develop active disease any time
during their lifetime [12]. If we knew the answer to
this question, we would be in a much better position
to design an effective TB vaccine [65]. From an evol-
utionary point of view, the low attack rate in active TB
suggeststhatMTBCisnotaparticularlygoodpathogen
intermsofcausingdisease,yet,consideringthe2billion
latently infected individuals, MTBC is extraordinarily
successful at generating secondary infections once
active TB develops. On a more provocative and highly
speculative note, infection with MTBC might in fact
bebeneﬁcialtoatleastsomehuman beings(i.e.individ-
uals who never develop active TB), perhaps because a
low level of constant immune-stimulation might protect
against other diseases. It is well known that the BCG
vaccine strain is a potent immune adjuvant which is
used to treat bladder cancer. Nevertheless, considering
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Figure 7. Evolutionarily ‘modern’ MTBC lineages are
associated with a shorter latency in human TB. TB patients
of 1808 HIV-negative household contacts were followed over
2 years. The number of active TB cases occurring in these
contacts during the study period was determined and strati-
ﬁed by the MTBC lineage of the index cases (solid line,
‘ancient’ MTBC (i.e. M. africanum), dashed line, ‘modern’
MTBC. Adapted from de Jong et al.[ 61].
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would seem inappropriate to label MTBC as a mere
commensal or even a symbiont.
Getting back to the coevolutionary question, some
evidence is gradually accumulating which suggests
that human genetic variation is indeed interacting
with MTBC diversity. At least four recent studies
have reported associations between particular human
genetic variants in immunity-related genes and differ-
ent MTBC lineages [66–69]. For example, one
study in Vietnam found that a particular SNP in
Toll-like receptor 2, a molecule known to be key in
innate immune recognition of MTBC, was associated
with infection by MTBC lineage 2 in TB patients.
Future studies will tell whether these associations
reﬂect reciprocal genetic changes characteristic of
host–pathogen evolution [46].
9. CONCLUDING REMARKS
In summary, current evidence suggests that human TB
originatedinAfricaandthatMTBChasbeenassociated
with its human host for a very long time. It is therefore
plausible that this extended host–pathogen association
has facilitated some degree of coevolution, and data
are accumulating that support this notion. Further-
more, changes in human demography could also have
played a role in the evolution of MTBC’s life history.
The thought that ‘modern’ MTBC has gained an evol-
utionary advantage compared with ‘ancient’ strains is
supported by the larger geographical spread of the
former. In addition, ‘ancient’ MTBC lineages appear
to be more constrained to their particular geography
and associated human populations, while ‘modern’
strains seem to be more promiscuous. Hence from an
ecological point of view, ‘ancient’ strains might be
referred to as ‘specialists’, while ‘modern’ MTBC
might represent ‘generalists’ [70]. Looking into the
future and considering the continued global human
populationincrease,coupledwithongoingglobalization
and urbanization, one wonders where the evolution of
human TB is headed. Will MTBC become even more
virulent and will particular strain variants become the
dominant forms all over the world [71]? Although
WHO has devised an ambitious plan to eliminate TB
as a global public health problem by 2050 [72], some
of the questions discussed here, while primarily of aca-
demic interest, should be taken into account by TB
researchers and public health ofﬁcials alike [73].
Answering them will help develop better tools and strat-
egies to control one of the world’s oldest and yet still
most important human diseases.
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